AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study

Molecular Therapy

Volumn 10, Issue 5, 2004, Pages 967-972

  Immonen, Arto ^a   Vapalahti, Matti ^a,b   Tyynelä, Kristiina ^a   Hurskainen, Heleena ^a   Sandmair, Anu ^a   Vanninen, Ritva ^a   Langford, Gillian ^c   Murray, Neil ^c   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Ark Therapeutics Group plc   (United Kingdom)

Author keywords

Adenovirus; Gene therapy; Malignant glioma; Survival; Thymidine kinase

Indexed keywords

CEREPRO; EG 009; GANCICLOVIR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; EXCISION; FEMALE; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; VIRAL GENE THERAPY;

ADENOVIRIDAE; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THYMIDINE KINASE;

ADENOVIRIDAE;

EID: 7044235842     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.08.002     Document Type: Article

References (24)

1. M. Salcman Supratentorial gliomas: Clinical features and surgical therapy. In: R.H. Wilkins S.S. Rengachary (Eds.). Neurosurgery 1996 McGraw-Hill New York 777-778
2. F.L. Moolten Drug sensitivity ("suicide") genes for selective cancer chemotherapy Cancer Gene Ther. 1 1994 279-287
3. K.W. Culver Z. Ram S. Wallbridge H. Ishii E.H. Oldfield R.M. Blaese In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumours Science 256 1992 1550-1552
4. Z. Ram et al. Therapy of malignant brain tumours by intra-tumoural implantation of retroviral vector-producing cells Nat. Med. 3 1997 1354-1361
5. S. Yla-Herttuala Gene therapy and brain tumours. In: T. Mikkelsen R. Bjerkvig O.D. Laerum M.L. Rosenblum (Eds.). Brain Tumour Invasion: Biological, Clinical, and Therapeutic Considerations 1998 Wiley-Liss, Inc New York 435-445
6. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis Nat. Med. 5 1999 1323-1327
7. A.M. Sandmair et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses Hum. Gene Ther. 11 2000 2197-2205
8. K.L. Hermann Antibody detection. In: E.H. Lennette P. Halonen F.A. Murphy (Eds.). Laboratory Diagnosis of Infectious Diseases. Principles and Practice Viral, Rickettsial, and Chlamydial Diseases vol II 1988 Springer-Verlag New York 82-86
9. M. Izquierdo et al. Long-term rat survival after malignant brain tumour regression by retroviral gene therapy Gene Ther. 2 1995 66-69
10. A.M. Sandmair et al. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: Effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions Cancer Gene Ther. 7 2000 413-421
11. K. Tyynela et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model Cancer Gene Ther. 9 2002 917-924
12. S.H. Chen H.D. Shine J.C. Goodman R.G. Grossman S.L. Woo Gene therapy for brain tumours: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo Proc. Natl. Acad. Sci. USA 91 1994 3054-3057
13. M.J. Perez-Cruet et al. Adenovirus-mediated gene therapy of experimental gliomas J. Neurosci. Res. 39 1994 506-511
14. A.M. Puumalainen et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses Hum. Gene Ther. 9 1998 1769-1774
15. D. Klatzmann et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma Hum. Gene Ther. 9 1998 2595-2604
16. N. Shand et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumour transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group Hum. Gene Ther. 10 1999 2325-2335
17. N.G. Rainov A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Hum. Gene Ther. 11 2000 2389-2401
18. K.J. Pulkkanen H. Sallinen K. Tyynelä S. Ylä-Herttuala Cancer gene therapy-current status in the clinics Gene Ther. Regul. 2004 (in press)
19. S.M. Freeman et al. The "bystander effect": Tumour regression when a fraction of the tumour mass is genetically modified Cancer Res. 53 1993 5274-5283
20. S.L. Eck et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial Hum. Gene Ther. 7 1996 1465-1482
21. T.W. Trask et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumours Mol. Ther. 1 2000 195-203
22. P.S. Smitt M. Driesse J. Wolbers M. Kros C. Avezaat Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir Mol. Ther. 7 2003 851-858
23. D. Nanda M.J. Dreisse P.A. Sillevis Smitt Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas Progr. Brain Res. 132 2001 699-710
24. C. Nyberg-Hoffman P. Shabram W. Li D. Giroux E. Aguilar-Cordova Sensitivity and reproducibility in adenoviral infectious titer determination Nat. Med. 3 1997 808-811